ARQT as reported
Arcutis Biotherapeutics, Inc. reported $464M of revenue over the trailing twelve months, +76% on the year before. 10 reported series are charted on this page, each one as filed.
$464M
Revenue, trailing twelve months · to Q2 2026 · +76% against the twelve months before
- Net Income
- $29M
Net Income · −131% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $39M
Free Cash Flow · −159% year on year · trailing twelve months to Q2 2026
- Op Margin
- 6.7%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $464M | +76% | Q2 2026 |
| Net Income | $29M | −131% | Q2 2026 |
| EPS | $0.21 | −128% | Q2 2026 |
| Gross Margin | 91% | n/a | Q2 2026 |
| Op Margin | 6.7% | n/a | Q2 2026 |
| Net Margin | 5.4% | n/a | Q2 2026 |
| ROE | −6.2% | n/a | Q2 2026 |
| ROA | −2.6% | n/a | Q2 2026 |
| ROIC | −4.8% | n/a | Q2 2026 |
| Free Cash Flow | $39M | −159% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Arcutis Biotherapeutics, Inc. (ARQT) - Revenue & ProfitRevenue & ProfitArcutis Biotherapeutics, Inc. (ARQT)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com